Muutke küpsiste eelistusi

Synopsis of Key Gynecologic Oncology Trials 2nd edition [Pehme köide]

5.00/5 (2 hinnangut Goodreads-ist)
, (Division of Gynecologic Oncology, NYU Grossman School of Medicine, NY, U), (Division of Gynecologic Oncology, Stanford University School of Medicine, USA), (Division of Gynecologic Oncology, Stanford University School of Medicine, USA)
  • Formaat: Paperback / softback, 160 pages, kõrgus x laius: 229x152 mm, kaal: 260 g
  • Ilmumisaeg: 06-Dec-2022
  • Kirjastus: CRC Press
  • ISBN-10: 1032135328
  • ISBN-13: 9781032135328
Teised raamatud teemal:
Synopsis of Key Gynecologic Oncology Trials 2nd editionSuurem pilt
  • Formaat: Paperback / softback, 160 pages, kõrgus x laius: 229x152 mm, kaal: 260 g
  • Ilmumisaeg: 06-Dec-2022
  • Kirjastus: CRC Press
  • ISBN-10: 1032135328
  • ISBN-13: 9781032135328
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9781032135328.html
Märksõnad:
This revised and updated new edition of a best-selling text remains a fast and convenient overview of the clinical trials in gynecologic cancer treatment, outlining the evidence base of treatment decisions in uterine, ovarian, cervical, and vulvar cancers, and gestational trophoblastic neoplasia. Residents and fellows will find this book an indispensable reference, while practitioners will welcome it as a clarification of the evidence base for treatment options.

*Gives a convenient summary of trials in gynecologic oncology *Supplies an invaluable revision primer for those undertaking certification *Provides a uniquely up-to-date resource
Preface to the Second Edition ix
1 Uterine Malignancies
1(42)
1.1 Endometrial Carcinoma
1(26)
1.1.1 Studies Addressing Surgical Treatment
1(2)
1.1.1.1 Lymph Node Assessment
3(5)
1.1.2 Studies Addressing Adjuvant Therapy
8(1)
1.1.2.1 Radiation
8(3)
1.1.2.2 Chemoradiation
11(4)
1.1.2.3 Chemotherapy
15(3)
1.1.3 Studies Addressing Treatment of Recurrent Endometrial Carcinoma
18(1)
1.1.3.1 Hormonal Therapy
18(2)
1.1.3.2 Chemotherapy
20(1)
1.1.3.3 Targeted Therapy
21(2)
1.1.3.4 Immunotherapy
23(4)
1.2 Uterine Carcinosarcoma
27(4)
1.2.1 Studies Addressing Prognosticators
27(1)
1.2.2 Studies Addressing Adjuvant Treatment
27(2)
1.2.3 Studies Addressing Treatment of Advanced/Recurrent Uterine Carcinosarcoma
29(2)
1.3 Uterine Leiomyosarcoma
31(12)
1.3.1 Studies Addressing Adjuvant Treatment of Early-Stage Uterine Leiomyosarcoma
31(2)
1.3.2 Studies Addressing Treatment of Advanced Uterine Leiomyosarcoma
33(4)
References
37(6)
2 Ovarian Malignancies
43(66)
2.1 Epithelial Ovarian Cancer
43(49)
2.1.1 Studies Addressing Upfront Surgery
43(1)
2.1.2 Studies Addressing Adjuvant Therapy
44(10)
2.1.3 Studies Addressing Intraperitoneal Chemotherapy
54(4)
2.1.4 Studies Addressing First-Line Maintenance Treatment
58(5)
2.1.5 Studies Addressing Neoadjuvant Therapy
63(3)
2.1.6 Studies Addressing Prediction of Debulking
66(2)
2.1.7 Studies Addressing Time Point of Treatment for Recurrence
68(1)
2.1.8 Studies Addressing Treatment of Recurrent Ovarian Cancer, Platinum Sensitive
69(1)
2.1.8.1 Chemotherapy and Targeted Therapy
69(13)
2.1.8.2 Secondary Debulking Surgery
82(3)
2.1.9 Studies Addressing Treatment of Recurrent Ovarian Cancer, Platinum Resistant
85(1)
2.1.9.1 Chemotherapy and Targeted Therapy
85(3)
2.1.9.2 Immunotherapy
88(4)
2.2 Low-Grade Serous Ovarian Cancer
92(2)
2.3 Mucinous Epithelial Ovarian Cancer
94(2)
2.4 Small-Cell Carcinoma of the Ovary
96(1)
2.5 Ovarian Germ Cell Tumors
96(1)
2.6 Ovarian Sex Cord-Stromal Tumors
97(12)
References
98(11)
3 Cervical Cancer
109(28)
3.1 Studies Addressing Surgical Treatment
109(4)
3.2 Studies Addressing Adjuvant Therapy
113(3)
3.3 Studies Addressing Primary Chemoradiation Therapy
116(8)
3.4 Studies Addressing Treatment of Recurrent or Metastatic Cervical Cancer
124(13)
3.4.1 Chemotherapy and Targeted Therapy
124(5)
3.4.2 Immunotherapy
129(3)
References
132(5)
4 Vulvar Cancer
137(10)
4.1 Studies Addressing Surgical Treatment
137(6)
4.1.1 Groin Lymph Nodes
140(3)
4.2 Studies Addressing Advanced Vulvar Cancer
143(4)
4.2.1 Chemoradiation
143(2)
4.2.2 Immunotherapy
145(1)
References
145(2)
5 Gestational Trophoblastic Neoplasia
147(8)
5.1 Studies Addressing Surgical Treatment
147(1)
5.2 Studies Addressing Chemotherapy in Low-Risk Gestational Trophoblastic Neoplasia
148(2)
5.3 Studies Addressing (Chemo)Therapy in High-Risk Gestational Trophoblastic Neoplasia
150(5)
References
153(2)
Glossary 155(2)
Index 157
Malte Renz, MD, PhD: Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, California, USA

Elisabeth J. Diver, MD: Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, California, USA

Whitfield B. Growdon, MD: Division of Gynecologic Oncology, NYU Grossman School of Medicine, New York, New York, USA

Oliver Dorigo, MD, PhD: Division of Gynecologic Oncology, Stanford University School of Medicine, Standford, California, USA